Loading clinical trials...
Loading clinical trials...
A Phase I, Multi Center, Open Label Study of CC-98633, BCMA Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed and/or Refractory Multiple Myeloma
Conditions
Interventions
CC-98633
Locations
11
United States
Local Institution - 103
Birmingham, Alabama, United States
Local Institution - 111
Phoenix, Arizona, United States
Local Institution - 110
Stanford, California, United States
Local Institution - 107
Chicago, Illinois, United States
Local Institution - 101
Westwood, Kansas, United States
Local Institution - 109
Rochester, Minnesota, United States
Start Date
August 18, 2020
Primary Completion Date
July 3, 2024
Completion Date
July 3, 2024
Last Updated
July 26, 2024
NCT06679101
NCT05969860
NCT06870760
NCT06057402
NCT06383143
NCT06285318
Lead Sponsor
Juno Therapeutics, a Subsidiary of Celgene
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions